{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:33:50Z","timestamp":1789702430900,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40478-018-0521-5","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T19:50:23Z","timestamp":1519847423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival"],"prefix":"10.1186","volume":"6","author":[{"given":"P. S.","family":"Zeiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Kowalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bernatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tichy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W.","family":"Ronellenfitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Thorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Beschorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wischhusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M.","family":"Kvasnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. H.","family":"Plate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stefanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mittelbronn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. N.","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"521_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","volume":"47","author":"T Ahrends","year":"2017","unstructured":"Ahrends T, Spanjaard A, Pilzecker B, B\u0105ba\u0142a N, Bovens A, Xiao Y, Jacobs H, Borst J (2017) CD4+T cell help confers a cytotoxic T cell effector program including Coinhibitory receptor downregulation and increased tissue invasiveness. Immunity 47:848\u2013861.e5. https:\/\/doi.org\/10.1016\/j.immuni.2017.10.009","journal-title":"Immunity"},{"key":"521_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, B\u00f8rresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfj\u00f6rd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinsk M, J\u00e4ger N, Jones DTW, Jonas D, Knappskog S, Koo M, Lakhani SR, L\u00f3pez-Ot\u00edn C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt ANJ, Vald\u00e9s-Mas R, Van Buuren MM, van \u2018t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Zucman-Rossi J, Andrew Futreal P, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR (2013) Signatures of mutational processes in human cancer. Nature 500:415\u2013421. https:\/\/doi.org\/10.1038\/nature12477","journal-title":"Nature"},{"key":"521_CR3","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. J Clin Oncol 22:2865\u20132872. https:\/\/doi.org\/10.1200\/JCO.2004.12.149","journal-title":"J Clin Oncol"},{"key":"521_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/ni.2225","volume":"13","author":"G Basha","year":"2012","unstructured":"Basha G, Omilusik K, Chavez-Steenbock A, Reinicke AT, Lack N, Choi KB, Jefferies WA (2012) A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nat Immunol 13:237\u2013245. https:\/\/doi.org\/10.1038\/ni.2225","journal-title":"Nat Immunol"},{"key":"521_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/his.12537","volume":"66","author":"AS Berghoff","year":"2015","unstructured":"Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, H\u00f6ller C, Preusser M (2015) Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 66:289\u2013299. https:\/\/doi.org\/10.1111\/his.12537","journal-title":"Histopathology"},{"key":"521_CR6","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-04-0182","volume":"10","author":"JD Burton","year":"2004","unstructured":"Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM (2004) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 10:6606\u20136611. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0182","journal-title":"Clin Cancer Res"},{"key":"521_CR7","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/0008-5472.CAN-04-1350","volume":"64","author":"MED Chamuleau","year":"2004","unstructured":"Chamuleau MED, Souwer Y, Van Ham SM, Zevenbergen A, Westers TM, Berkhof J, Meijer CJ, Van De Loosdrecht AA, Ossenkoppele GJ (2004) Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 64:5546\u20135550. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1350","journal-title":"Cancer Res"},{"key":"521_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1744-313X.1995.tb00246.x","volume":"22","author":"A Concha","year":"1995","unstructured":"Concha A, Ruiz-Cabello F, Cabrera T, Nogales F, Collado A, Garrido F (1995) Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast. Int J Immunogenet 22:299\u2013310. https:\/\/doi.org\/10.1111\/j.1744-313X.1995.tb00246.x","journal-title":"Int J Immunogenet"},{"key":"521_CR9","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.ejca.2009.02.005","volume":"45","author":"RJ Cuthbert","year":"2009","unstructured":"Cuthbert RJ, Wilson JM, Scott N, Coletta PL, Hull MA (2009) Differential CD74 (major histocompatibility complex class II invariant chain) expression in mouse and human intestinal adenomas. Eur J Cancer 45:1654\u20131663. https:\/\/doi.org\/10.1016\/j.ejca.2009.02.005","journal-title":"Eur J Cancer"},{"key":"521_CR10","doi-asserted-by":"publisher","first-page":"12073","DOI":"10.1073\/pnas.0903852106","volume":"106","author":"FR Depontieu","year":"2009","unstructured":"Depontieu FR, Qian J, Zarling AL, McMiller TL, Salay TM, Norris A, English AM, Shabanowitz J, Engelhard VH, Hunt DF, Topalian SL (2009) Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A 106:12073\u201312078. https:\/\/doi.org\/10.1073\/pnas.0903852106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"521_CR11","doi-asserted-by":"publisher","unstructured":"Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE (2016) Expression of the MHC class II pathway in triple-negative breast cancer tumor cells is associated with a good prognosis and infiltrating lymphocytes. Cancer Immunol Res:1\u201311. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0243","DOI":"10.1158\/2326-6066.CIR-15-0243"},{"key":"521_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s11060-015-1977-9","volume":"126","author":"C Frenard","year":"2016","unstructured":"Frenard C, Peuvrel L, Jean MS, Brocard A, Knol AC, Nguyen JM, Khammari A, Quereux G, Dreno B (2016) Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. J Neuro-Oncol 126:355\u2013360. https:\/\/doi.org\/10.1007\/s11060-015-1977-9","journal-title":"J Neuro-Oncol"},{"key":"521_CR13","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","volume":"33","author":"SN Gettinger","year":"2015","unstructured":"Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:2004\u20132012. https:\/\/doi.org\/10.1200\/JCO.2014.58.3708","journal-title":"J Clin Oncol"},{"key":"521_CR14","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3892\/ijo.2016.3387","volume":"48","author":"KM Goudarzi","year":"2016","unstructured":"Goudarzi KM, Lindstr\u00f6m MS (2016) Role of ribosomal protein mutations in tumor development (review). Int J Oncol 48:1313\u20131324. https:\/\/doi.org\/10.3892\/ijo.2016.3387","journal-title":"Int J Oncol"},{"key":"521_CR15","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1093\/nar\/gku480","volume":"42","author":"M Hannus","year":"2014","unstructured":"Hannus M, Beitzinger M, Engelmann JC, Weickert MT, Spang R, Hannus S, Meister G (2014) SiPools: highly complex but accurately defined siRNA pools eliminate off-target effects. Nucleic Acids Res 42:8049\u20138061. https:\/\/doi.org\/10.1093\/nar\/gku480","journal-title":"Nucleic Acids Res"},{"key":"521_CR16","doi-asserted-by":"publisher","first-page":"40836","DOI":"10.18632\/oncotarget.5696","volume":"6","author":"PN Harter","year":"2015","unstructured":"Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M (2015) Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1\/PD-L1 immune checkpoints in human brain metastases. Oncotarget 6:40836\u201340849. https:\/\/doi.org\/10.18632\/oncotarget.5696","journal-title":"Oncotarget"},{"key":"521_CR17","doi-asserted-by":"publisher","unstructured":"Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim S-R, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O\u2019Toole S, Larsimont D, de Wind R, Curigliano G, Andr\u00e9 F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international Immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol doi. https:\/\/doi.org\/10.1097\/PAP.0000000000000161","DOI":"10.1097\/PAP.0000000000000161"},{"key":"521_CR18","doi-asserted-by":"publisher","unstructured":"Ilina EI, Armento A, Sanchez LG, Reichlmeir M, Braun Y, Penski C, Capper D, Sahm F, Jennewein L, Harter PN, Zukunft S, Fleming I, Schulte D, Le F, Behrends C, Ronellenfitsch MW, Naumann U, Mittelbronn M (2017) Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.18747","DOI":"10.18632\/oncotarget.18747"},{"key":"521_CR19","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nmeth1113","volume":"4","author":"L K\u00e4ll","year":"2007","unstructured":"K\u00e4ll L, Canterbury JD, Weston J, Noble WS, MacCoss MJ (2007) Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods 4:923\u2013925. https:\/\/doi.org\/10.1038\/nmeth1113","journal-title":"Nat Methods"},{"key":"521_CR20","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-05-1852","volume":"12","author":"N Koide","year":"2006","unstructured":"Koide N, Yamada T, Shibata R, Mori T, Fukuma M, Yamazaki K, Aiura K, Shimazu M, Hirohashi S, Nimura Y, Sakamoto M (2006) Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clin Cancer Res 12:2419\u20132426. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1852","journal-title":"Clin Cancer Res"},{"key":"521_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-62703-218-6_12","volume":"960","author":"DJ Kowalewski","year":"2013","unstructured":"Kowalewski DJ, Stefanovi\u0107 S (2013) Biochemical large-scale identification of MHC class I ligands. Methods Mol Biol 960:145\u2013157. https:\/\/doi.org\/10.1007\/978-1-62703-218-6_12","journal-title":"Methods Mol Biol"},{"key":"521_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter S, Vormehr M, van de Roemer N, Diken M, L\u00f6wer M, Diekmann J, Boegel S, Schr\u00f6rs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, T\u00fcreci \u00d6, Sahin U (2015) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520:692\u2013696. https:\/\/doi.org\/10.1038\/nature14426","journal-title":"Nature"},{"key":"521_CR23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000011870","volume":"55","author":"M Kunihiro","year":"1998","unstructured":"Kunihiro M, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F (1998) Combined expression of HLA-DR antigen and proliferating cell nuclear antigen correlate with colorectal cancer prognosis. Oncology 55:326\u2013333. https:\/\/doi.org\/10.1159\/000011870","journal-title":"Oncology"},{"key":"521_CR24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00022744-200109000-00007","volume":"9","author":"B Lazzaro","year":"2001","unstructured":"Lazzaro B, Anderson AE, Kajdacsy-Balla A, Hessner MJ (2001) Antigenic characterization of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases. Appl Immunohistochem Mol Morphol 9:234\u2013241","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"521_CR25","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"521_CR26","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1084\/jem.20030286","volume":"197","author":"L Leng","year":"2003","unstructured":"Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197:1467\u20131476. https:\/\/doi.org\/10.1084\/jem.20030286","journal-title":"J Exp Med"},{"key":"521_CR27","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.3748\/wjg.v16.i26.3258","volume":"16","author":"N Maharshak","year":"2010","unstructured":"Maharshak N, Cohen S, Lantner F, Hart G, Leng L, Bucala R, Shachar I (2010) CD74 is a survival receptor on colon epithelial cells. World J Gastroenterol 16:3258\u20132366. https:\/\/doi.org\/10.3748\/wjg.v16.i26.3258","journal-title":"World J Gastroenterol"},{"key":"521_CR28","doi-asserted-by":"publisher","first-page":"638","DOI":"10.2353\/ajpath.2009.080463","volume":"174","author":"M McClelland","year":"2009","unstructured":"McClelland M, Zhao L, Carskadon S, Arenberg D (2009) Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am J Pathol 174:638\u2013646. https:\/\/doi.org\/10.2353\/ajpath.2009.080463","journal-title":"Am J Pathol"},{"key":"521_CR29","doi-asserted-by":"publisher","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C (2017) Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. https:\/\/doi.org\/10.1016\/j.cell.2017.10.001","DOI":"10.1016\/j.cell.2017.10.001"},{"key":"521_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00008390-199708000-00006","volume":"7","author":"S Moretti","year":"1997","unstructured":"Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM, Giannotti B (1997) In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7:313\u2013321","journal-title":"Melanoma Res"},{"key":"521_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/jso.2930590407","volume":"59","author":"M Morita","year":"1995","unstructured":"Morita M, Tanaka K, Kawanishi H, Tsuji M, Ookusa T, Takada H, Okamura A, Hioki K (1995) Immunohistochemically demonstrated expression of HLA-DR antigen in colorectal adenocarcinomas and its relation to clinicopathological features. J Surg Oncol 59:233\u2013238. https:\/\/doi.org\/10.1002\/jso.2930590407","journal-title":"J Surg Oncol"},{"key":"521_CR32","doi-asserted-by":"publisher","unstructured":"M\u00fcller M, Gfeller D, Coukos G, Bassani-Sternberg M (2017) \u201cHotspots\u201d of antigen presentation revealed by human leukocyte antigen ligandomics for neoantigen prioritization. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.01367","DOI":"10.3389\/fimmu.2017.01367"},{"key":"521_CR33","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1245\/s10434-009-0532-3","volume":"16","author":"S Nagata","year":"2009","unstructured":"Nagata S, Jin YF, Yoshizato K, Tomoeda M, Song M, Iizuka N, Kitamura M, Takahashi H, Eguchi H, Ohigashi H, Ishikawa O, Tomita Y (2009) CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann Surg Oncol 16:2531\u20132538. https:\/\/doi.org\/10.1245\/s10434-009-0532-3","journal-title":"Ann Surg Oncol"},{"key":"521_CR34","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/bjc.2017.142","volume":"116","author":"S Parakh","year":"2017","unstructured":"Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, Mcarthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS (2017) Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer 116:1558\u20131563. https:\/\/doi.org\/10.1038\/bjc.2017.142","journal-title":"Br J Cancer"},{"key":"521_CR35","doi-asserted-by":"publisher","unstructured":"Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP (2017) Identification of essential genes for cancer immunotherapy. Nature. https:\/\/doi.org\/10.1038\/nature23477","DOI":"10.1038\/nature23477"},{"key":"521_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nri1708","volume":"5","author":"W Reith","year":"2005","unstructured":"Reith W, LeibundGut-Landmann S, Waldburger JM (2005) Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 5:793\u2013806. https:\/\/doi.org\/10.1038\/nri1708","journal-title":"Nat Rev Immunol"},{"key":"521_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372:150419053123009. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"521_CR38","doi-asserted-by":"publisher","unstructured":"Rotte A, Jin JY, Lemaire V (2017) Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol:1\u201313. https:\/\/doi.org\/10.1093\/annonc\/mdx686","DOI":"10.1093\/annonc\/mdx686"},{"key":"521_CR39","doi-asserted-by":"publisher","unstructured":"Schuster H, Peper JK, B\u00f6sm\u00fcller HC, R\u00f6hle K, Backert L, Bilich T, Ney B, L\u00f6ffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee H-G, Stefanovi\u0107 S, Staebler A, Wagner P (2017) The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci 201707658. https:\/\/doi.org\/10.1073\/pnas.1707658114","DOI":"10.1073\/pnas.1707658114"},{"key":"521_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1593\/neo.131568","volume":"16","author":"G Sconocchia","year":"2014","unstructured":"Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, Droeser R, Rossi P, Attanasio A, Ferrone S, Terracciano L (2014) HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia 16:31\u201342. https:\/\/doi.org\/10.1593\/neo.131568","journal-title":"Neoplasia"},{"key":"521_CR41","doi-asserted-by":"publisher","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med:2189\u20132199. https:\/\/doi.org\/10.1056\/NEJMoa1406498","DOI":"10.1056\/NEJMoa1406498"},{"key":"521_CR42","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/eji.201545930","volume":"46","author":"A Sofron","year":"2016","unstructured":"Sofron A, Ritz D, Neri D, Fugmann T (2016) High-resolution analysis of the murine MHC class II immunopeptidome. Eur J Immunol 46:319\u2013328. https:\/\/doi.org\/10.1002\/eji.201545930","journal-title":"Eur J Immunol"},{"key":"521_CR43","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JPS, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419\u2013425. https:\/\/doi.org\/10.1200\/JCO.2011.38.0527","journal-title":"J Clin Oncol"},{"key":"521_CR44","doi-asserted-by":"publisher","unstructured":"Steimle V, Siegrist C, Mottet A, Lisowska-Grospierre B, Mach B (1994) Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science (80- ) 265:106\u2013109. https:\/\/doi.org\/10.1126\/science.8016643","DOI":"10.1126\/science.8016643"},{"key":"521_CR45","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/0008-5472.CAN-12-3514","volume":"73","author":"T Sundstrom","year":"2013","unstructured":"Sundstrom T, Daphu I, Wendelbo I, Hodneland E, Lundervold A, Immervoll H, Skaftnesmo KO, Babic M, Jendelova P, Sykova E, Lund-Johansen M, Bjerkvig R, Thorsen F (2013) Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model. Cancer Res 73:2445\u20132456. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3514","journal-title":"Cancer Res"},{"key":"521_CR46","first-page":"113","volume":"3","author":"PE Swanson","year":"1990","unstructured":"Swanson PE, Wick MR (1990) HLA-DR (Ia-like) reactivity in tumors of bone and soft tissue: an immunohistochemical comparison of monoclonal antibodies LN3 and LK8D3 in routinely processed specimens. Mod Pathol 3:113\u2013119","journal-title":"Mod Pathol"},{"key":"521_CR47","doi-asserted-by":"publisher","unstructured":"Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA (2015) Cell surface CD74\u2013MIF interactions drive melanoma survival in response to interferon-\u03b3. J Invest Dermatol. https:\/\/doi.org\/10.1038\/jid.2015.259","DOI":"10.1038\/jid.2015.259"},{"key":"521_CR48","first-page":"433","volume":"46","author":"D Taramelli","year":"1986","unstructured":"Taramelli D, Fossati G, Mazzocchi A, Parmiani G, Delia D, Ferrone S (1986) Classes i and ii hla and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res 46:433\u2013439","journal-title":"Cancer Res"},{"key":"521_CR49","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/annonc\/mdx195.002","volume":"28","author":"MS Tsao","year":"2017","unstructured":"Tsao MS, Le Teuff G, Shepherd FA, Landais C, Hainaut P, Filipits M, Pirker R, Le Chevalier T, Graziano S, Kratze R, Soria JC, Pignon JP, Seymour L, Brambilla E (2017) PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. Ann Oncol 28:882\u2013889. https:\/\/doi.org\/10.1093\/annonc\/mdx003","journal-title":"Ann Oncol"},{"key":"521_CR50","doi-asserted-by":"publisher","first-page":"44159","DOI":"10.18632\/oncotarget.17395","volume":"8","author":"TB Turner","year":"2017","unstructured":"Turner TB, Meza-Perez S, Londo\u00f1o A, Katre A, Peabody JE, Smith HJ, Forero A, Norian LA, Straughn JM, Buchsbaum DJ, Randall TD, Arend RC (2017) Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Oncotarget 8:44159\u201344170. https:\/\/doi.org\/10.18632\/oncotarget.17395","journal-title":"Oncotarget"},{"key":"521_CR51","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gkv1145","volume":"44","author":"JA Vizca\u00edno","year":"2016","unstructured":"Vizca\u00edno JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, Xu QW, Wang R, Hermjakob H (2016) 2016 update of the PRIDE database and its related tools. Nucleic Acids Res 44:D447\u2013D456. https:\/\/doi.org\/10.1093\/nar\/gkv1145","journal-title":"Nucleic Acids Res"},{"key":"521_CR52","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/eji.201343671","volume":"44","author":"S W\u00e4lchli","year":"2014","unstructured":"W\u00e4lchli S, Kumari S, Fallang LE, Sand KMK, Yang W, Landsverk OJB, Bakke O, Olweus J, Gregers TF (2014) Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation. Eur J Immunol 44:774\u2013784. https:\/\/doi.org\/10.1002\/eji.201343671","journal-title":"Eur J Immunol"},{"key":"521_CR53","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2990.2010.01119.x","volume":"37","author":"J Wang","year":"2011","unstructured":"Wang J, Daphu I, Pedersen PH, Miletic H, Hovland R, M\u00f8rk S, Bjerkvig R, Tiron C, McCormack E, Micklem D, Lorens JB, Immervoll H, Thorsen F (2011) A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Neuropathol Appl Neurobiol 37:189\u2013205. https:\/\/doi.org\/10.1111\/j.1365-2990.2010.01119.x","journal-title":"Neuropathol Appl Neurobiol"},{"key":"521_CR54","doi-asserted-by":"publisher","unstructured":"Wang ZQ, Milne K, Webb JR, Watson PH (2017) CD74 and intratumoral immune response in breast cancer. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.8610","DOI":"10.18632\/oncotarget.8610"},{"key":"521_CR55","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122\u2013133. https:\/\/doi.org\/10.1056\/NEJMoa1302369","journal-title":"N Engl J Med"},{"key":"521_CR56","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.it.2006.07.007","volume":"27","author":"KL Wright","year":"2006","unstructured":"Wright KL, Ting JPY (2006) Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 27:405\u2013412. https:\/\/doi.org\/10.1016\/j.it.2006.07.007","journal-title":"Trends Immunol"},{"key":"521_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bpa.12194","volume":"25","author":"PS Zeiner","year":"2015","unstructured":"Zeiner PS, Preusse C, Blank AE, Zachskorn C, Baumgarten P, Caspary L, Braczynski AK, Weissenberger J, Bratzke H, Rei\u00df S, Pennartz S, Winkelmann R, Senft C, Plate KH, Wischhusen J, Stenzel W, Harter PN, Mittelbronn M (2015) MIF receptor CD74 is restricted to microglia\/macrophages, associated with a M1-polarized immune milieu and prolonged patient survival in gliomas. Brain Pathol 25:491\u2013504. https:\/\/doi.org\/10.1111\/bpa.12194","journal-title":"Brain Pathol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-018-0521-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:29:29Z","timestamp":1751416169000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-018-0521-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1186\/s40478-018-0521-5","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,1]]},"assertion":[{"value":"17 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written consent was obtained from each patient. The study protocol was endorsed by the local ethical committee (Goethe-University Medical School\/UCT Frankfurt GS-04\/09, SNO-08-2015).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"18"}}